Rare disease database aims to boost cystinosis care across europe

NCT ID NCT05901077

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This European study will follow 400 people with cystinosis, a rare genetic disease that causes cystine buildup in cells. Researchers will collect medical and quality-of-life data to understand how the disease progresses and how care can be improved. The study does not test any new treatment but aims to provide insights that could lead to better management of the condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help doctors better understand cystinosis and improve care guidelines for patients across Europe.

What could go wrong

This is an observational study, not a treatment trial. It will not test any new drug or therapy, so direct patient benefits are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTINOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystinosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • RaDiCo-ECYSCO

    RECRUITING

    Paris, Île-de-France Region, 75012, France

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••